Gilead Sciences GILD Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

IncyteINCY

$38.27M-9.8%

ImmunityBio, Inc.IBRX

$445.39M+32.2%

PrecigenPGEN

$98.25M+1,714%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

Iovance Biotherapeutics, Inc.IOVA

$46.78M-11.3%

FAQ

What is Gilead Sciences's total debt?

Gilead Sciences (GILD) reported total debt of $22.17B in Q1 2026.

How has Gilead Sciences's total debt changed year-over-year?

Gilead Sciences's total debt decreased by 11.1% year-over-year, from $24.95B to $22.17B.

What is the long-term trend for Gilead Sciences's total debt?

Over 5 years (2020 to 2025), Gilead Sciences's total debt has grown at a -4.5% compound annual growth rate (CAGR), from $32.12B to $25.54B.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.